John B. Harlow, Jr. is the Chief Commercial Officer at Esperion Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing therapies to reduce cardiovascular risk. With more than 25 years of experience in the pharmaceutical and biotechnology sectors, Harlow has established himself as a seasoned leader in commercial strategy, sales execution, and market access. His career is marked by a proven track record of successfully launching innovative products and driving revenue growth in competitive therapeutic areas. Prior to joining Esperion in 2021, Harlow served as Vice President of U.S. Commercial Operations at Ironwood Pharmaceuticals, where he led the commercial launch and expansion of LINZESS®, the leading prescription therapy for irritable bowel syndrome with constipation and chronic idiopathic constipation, achieving blockbuster status. Earlier roles included senior positions at Cubist Pharmaceuticals (acquired by Merck), Genzyme Corporation (acquired by Sanofi), and Sepracor (acquired by Sunovion), where he spearheaded commercial efforts for antibiotics, rare disease therapies, and CNS products, consistently delivering multi-hundred-million-dollar annual revenues and market leadership. In his current role at Esperion, Harlow oversees the global commercial organization, including sales, marketing, market access, and medical affairs. He has been instrumental in the U.S. launches of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), the company's first-in-class, oral, once-daily, non-statin LDL-C lowering therapies. Under his leadership, Esperion has expanded patient access, built a robust commercial infrastructure, and positioned the company for sustained growth in the cardiovascular disease market.